

Datasheet for ABIN2749025
anti-TNFRSF12A antibody[Go to Product page](#)**2** Images**3** Publications

Overview

Quantity:	0.1 mg
Target:	TNFRSF12A
Reactivity:	Human, Mouse
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This TNFRSF12A antibody is un-conjugated
Application:	Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Functional Studies (Func)

Product Details

Immunogen:	human CD266-transfected P815 cells
Clone:	ITEM-4
Isotype:	IgG2b
Specificity:	The mouse monoclonal antibody ITEM-4 recognizes an extracellular epitope of CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.
Cross-Reactivity (Details):	Human, Mouse
Purification:	Purified by protein-A affinity chromatography.
Purity:	> 95 % (by SDS-PAGE)
Endotoxin Level:	Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL test.

Target Details

Target:	TNFRSF12A
Alternative Name:	CD266 / TWEAK R (TNFRSF12A Products)
Background:	TNF receptor superfamily member 12A,CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.,TWEAKR, FN14, TNFRSF12A
Gene ID:	51330
UniProt:	Q9NP84
Pathways:	Apoptosis , Regulation of Cell Size

Application Details

Application Notes:	Functional application: Blocking. Flow cytometry: Recommended dilution: 1-4 µg/mL
Restrictions:	For Research Use only

Handling

Concentration:	1 mg/mL
Buffer:	Phosphate buffered saline (PBS), pH 7.4
Preservative:	Azide free
Storage:	4 °C
Storage Comment:	Store at 2-8°C. Do not freeze.


Publications

Product cited in:	Yoriki, Akashi, Sho, Nomi, Yamato, Hotta, Takayama, Matsumoto, Wakatsuki, Migita, Yagita, Nakajima: "Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: Experimental and therapeutic medicine , Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).
-------------------	---

Roos, Wicovsky, Müller, Salzmann, Rosenthal, Kalthoff, Trauzold, Seher, Henkler, Kneitz, Wajant: "Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway." in: **Journal of immunology (Baltimore, Md. : 1950)**, Vol. 185, Issue 3, pp. 1593-605, (2010) ([PubMed](#)).


Nakayama, Ishidoh, Kojima, Harada, Kominami, Okumura, Yagita: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death." in: **Journal of immunology (Baltimore, Md. : 1950)**, Vol. 170, Issue 1, pp. 341-8, (2002) ([PubMed](#)).

Images



Flow Cytometry

Image 1. Flow cytometry surface staining pattern of HUVEC cells stained using anti-human CD266 (ITEM-4) purified antibody (low endotoxin, concentration in sample 1 µg/mL) GAM APC.



Flow Cytometry

Image 2. Separation of HUVEC cells stained using anti-human CD266 (ITEM-4) purified antibody (low endotoxin, concentration in sample 1 µg/mL, GAM APC, red-filled) from HUVEC cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).